GRAIL, Inc. Common Stock
GRALV
NASDAQ18.63
USD
+1.41
- -
GRAIL, Inc. Common Stock
GRALV
(NASDAQ)
Recent
price
18.63
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- GRAIL, Inc. GRAIL, Inc. (GRALV) is a commercial-stage healthcare company that develops and commercializes multi-cancer early detection (MCED) technologies using next-generation sequencing, population-scale clinical studies, machine learning, software, and automation to identify multiple deadly cancer types in earlier stages; its flagship product is the Galleri test, a blood-based liquid biopsy that screens for over 50 cancer types, including more than 45 without recommended screening today, by analyzing circulating tumor DNA methylation patterns; the company also offers development services supporting clinical studies, pilot testing, research, therapy development, minimal residual disease (MRD) post-diagnostic tests, risk stratification, biomarker subtyping, and recurrence monitoring. GRAIL, Inc. operates in the diagnostics and precision oncology segments, targeting individuals without symptoms, healthcare providers, insurers, and Medicare populations, with geographic presence in the United States, United Kingdom, and expansions into Asia. Founded in 2015 and headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the UK, the company was spun off from Illumina, Inc. Illumina, Inc. in June 2024 after EU regulatory requirements, with Illumina retaining a 14.5% stake. Recent developments include a $325 million private placement financing in October 2025 from institutional investors such as Deep Track Capital, Farallon Capital Management, Hims & Hers, and Braidwell LP to fund commercial activities, reimbursement efforts, and operations; a strategic collaboration announced in October 2025 with Samsung C&T and Samsung Electronics involving a $110 million equity investment and exclusive distribution of the Galleri test in South Korea, with potential expansion to Japan and Singapore, alongside explorations of AI and digital health integrations; presentation of PATHFINDER 2 study results at the European Society for Medical Oncology (ESMO) Congress in November 2025 demonstrating performance and safety data; and ongoing efforts for U.S. reimbursement including TRICARE coverage, partnerships with Quest Diagnostics and athenahealth for accessibility, and rollout of an enhanced Galleri test to reduce costs.